IPM Take
The GLP-1 revolution was built around molecules. The next commercial battle may be built around calendars.
Novo’s new agreement with Swedish drug-delivery company Nanexa gives it exclusive global access to the PharmaShell platform for up to five peptide programmes across obesity, type 2 diabetes and other cardiometabolic diseases. Monthly and quarterly dosing are explicit target profiles. Nanexa is eligible for payments of up to €1.165 billion, including €615 million combining the upfront payment with development and regulatory milestones, followed by sales milestones and low single-digit royalties. The standalone upfront payment has not been publicly separated from the milestone package. PR Newswire
That distinction matters. So does another one.
Nanexa has shown preclinical pharmacokinetic data suggesting PharmaShell-coated semaglutide could support much longer dosing intervals, including quarterly administration. But those results came from rat studies and human pharmacokinetic modelling, not clinical trials in people. Nanexa AB
The strategic signal is therefore stronger than the clinical one.
The industry increasingly believes convenience itself could become a differentiator in cardiometabolic medicine.
Executive Summary
Novo and Nanexa have entered a global exclusive licence and collaboration agreement covering PharmaShell for selected therapeutic peptides in obesity, type 2 diabetes and other cardiometabolic conditions. Novo can use the platform in up to five development programmes and will lead global development and commercialisation. PR Newswire
PharmaShell uses atomic layer deposition, a manufacturing technique adapted from fields such as semiconductor production, to apply an extremely thin inorganic coating around individual drug particles. Nanexa says controlling the coating can regulate how quickly the active pharmaceutical ingredient is released after injection while maintaining high drug loading. Nanexa AB
The companies are targeting administration intervals including monthly and quarterly injections. The specific peptides and programmes covered by the Novo agreement have not been disclosed. PR Newswire
Separately, Nanexa reported preclinical data in March showing prolonged release from PharmaShell-coated semaglutide formulations in rats and human pharmacokinetic simulations compatible with a potential quarterly dosing profile. That programme provides proof of concept for the platform, but not evidence that quarterly semaglutide is safe or effective in humans. Nanexa AB
Why it matters
- HTA bodies: Longer-acting formulations may eventually require assessment beyond efficacy alone. Dosing frequency could affect adherence, persistence, administration burden and patient preference, but those advantages will need to be demonstrated rather than assumed.
- Payers: Monthly or quarterly treatment could simplify chronic therapy for some patients, but it may also create new questions around acquisition cost, treatment discontinuation and what happens when adverse effects occur after a long-acting depot has already been administered.
- Industry / innovation partners: Drug delivery is becoming a competitive asset in its own right. As more companies converge on similar metabolic pathways, formulation and dosing convenience may become increasingly important ways to differentiate products.
Weekly injections helped redefine the treatment of obesity and type 2 diabetes.
Now drug developers are asking whether weekly is still too often.
Novo’s latest licensing agreement puts that question at the centre of a potentially €1.165 billion collaboration with Nanexa, a Swedish company developing long-acting injectable drug technology.
The agreement covers up to five peptide programmes in obesity, type 2 diabetes and other cardiometabolic diseases, with Novo receiving a global exclusive licence to Nanexa’s PharmaShell platform for specified drugs. Monthly and quarterly administration are among the target dosing profiles. PR Newswire
The technology takes an unusual manufacturing approach.
PharmaShell uses atomic layer deposition, or ALD, to coat individual drug particles with an extremely thin layer of slowly dissolving inorganic material. Nanexa has described coatings of around 30 nanometres in its semaglutide development work. By modifying the coating properties, the company aims to control the rate at which the underlying active ingredient is released after injection. Nanexa AB
In principle, that creates a drug depot capable of releasing a peptide gradually over weeks or months.
That could matter considerably in cardiometabolic medicine.
The current generation of injectable GLP-1 therapies has already moved the market away from daily administration toward weekly dosing. Reducing that burden further could potentially improve convenience and persistence, particularly for treatments intended to continue for years.
But the longer interval also changes the clinical equation.
Once a long-acting depot has been administered, clinicians cannot simply stop exposure the next day. Dose titration, tolerability, adverse-event management and reversibility become particularly important considerations when the dosing interval stretches from one week toward one or three months.
Those questions have not yet been answered for the Novo programmes because no candidates have been disclosed and clinical testing under the collaboration has not been announced.
Nanexa’s separate semaglutide programme provides an early indication of what the platform is designed to achieve.
In January, the company reported rat pharmacokinetic data supporting development of a monthly semaglutide formulation. In March, it reported additional rat studies showing ultra-long release and used those data in human pharmacokinetic simulations supporting the feasibility of quarterly administration. Nanexa AB
“Feasibility” is the operative word.
Those findings do not show that a person can receive semaglutide once every three months with equivalent efficacy, tolerability or safety to currently approved regimens. That would require human clinical development.
The Novo agreement nevertheless represents substantial commercial validation for the platform.
The relationship is also not new. Nanexa disclosed an evaluation agreement with Novo in 2022 under which the pharmaceutical company assessed PharmaShell for one of its own compounds. Nanexa’s 2024 annual report described continued work to optimise the formulation and produce material for additional Novo studies. Nanexa AB
The new agreement takes that relationship much further.
Novo will now lead development and commercialisation across as many as five programmes. Nanexa can receive up to €1.165 billion if the agreed milestones are reached, alongside low single-digit royalties on future net sales. Importantly, the €615 million figure cited in the agreement combines the upfront consideration with potential development and regulatory milestones. The remaining potential payments are linked to sales. PR Newswire
The deal also follows another major Novo platform agreement this month. The company recently committed up to $1.4 billion to Orbis Medicines to discover orally available macrocycles for cardiometabolic targets.
Those two strategies point in apparently opposite directions, but they are addressing the same problem.
One aims to make sophisticated cardiometabolic medicines easier to swallow.
The other aims to make injections dramatically less frequent.
Both suggest that the next generation of metabolic innovation will be judged not only by how much weight patients lose or how well glucose is controlled, but by how realistically treatment fits into everyday life.
That makes drug delivery more than a manufacturing detail.
It is becoming part of the medicine itself.
